

WORLD HEALTH ORGANIZATION COLLABORATING CENTRE FOR

*GOVERNANCE, ACCOUNTABILITY & TRANSPARENCY
IN THE PHARMACEUTICAL SECTOR*

Annual Report

October 2021 - OCTOBER 2022

Director

Dr. Jillian C. Kohler

COPYRIGHT © 2022

WHO WE ARE

This WHO CC involves the following multidisciplinary team of directors, faculty members, and research fellows:

Directors

DR. JILLIAN C. KOHLER

Director

*Leslie Dan Faculty of Pharmacy
University of Toronto*

DEIRDRE DIMANCESCO

Responsible Officer

*WHO Department of Health Products Policy and
Standards*

Research Fellows at University of Toronto

DR. SUZANNE CADARETTE

*Associate Professor
Leslie Dan Faculty of
Pharmacy*

DR. ERICA DI RUGGIERO

*Associate Professor
Dalla Lana School of Public
Health*

DR. LISA FORMAN

*Associate Professor
Dalla Lana School of Public
Health*

**DR. PAUL
GROOTENDORST**

*Associate Professor
Leslie Dan Faculty of
Pharmacy*

DR. QUINN GRUNDY

*Assistant Professor
Lawrence S. Bloomberg Faculty
of Nursing*

DR. TRUDO LEMMENS

*Professor
Faculty of Law,
University of Toronto*

DR. JOEL LEXCHIN

*Associate Professor
Temerty Faculty of
Medicine*

DR. ANITA MCGAHAN

*Professor
Rotman School of Management*

DR. NAV PERSAUD

*Scientist
Li Ka Sing Knowledge
Institute*

DR. ALISON THOMPSON

*Associate Professor
Leslie Dan Faculty of
Pharmacy*

DR. MINA TADROUS

*Assistant Professor
Leslie Dan Faculty of
Pharmacy*

DR. SHERYL SPITHOFF

*Assistant Professor
Temerty Faculty of
Medicine*

Research Fellows Outside University of Toronto

**DR. MARC-ANDRÉ
GAGNON**

Associate Professor
*School of Public
Policy & Administration
(Carleton University)*

DR. TIM K. MACKEY

Professor
Global Health Program
*(University of California,
San Diego)*

DR. KATHY MOSCOU

Adjunct Professor
Faculty of Applied Health
Sciences
(Brock University)

DR. KATRINA PEREHUDOFF

Senior Research Fellow and Co-Director
*Law Centre for Health and Life
Amsterdam Law school
(University of Amsterdam)*

DR. TARYN VIAN

Professor and Statewide MPH Director
*School of Nursing and Health Professions
(University of San Francisco)*

Contact Us:

Leslie Dan Faculty of Pharmacy
University of Toronto
144 College Street
Toronto, Ontario, M5S3M2
Tel: 416-946-8708 | Fax: 416-978-1833
Email: jillian.kohler@utoronto.ca
Website: <http://www.pharmacy.utoronto.ca/whocc>

Director's Note:

I am pleased to present the 2021-2022 Annual Report for the World Health Organization Collaborating Centre (WHO CC) for Governance, Accountability, and Transparency in the Pharmaceutical Sector. Established at the Leslie Dan Faculty of Pharmacy at the University of Toronto in 2015, the WHO CC assembles leading governance and related experts who partake in critical research and policy work on issues relating to accountability, transparency, and governance in the pharmaceutical sector on the global problem of corruption.

The key objectives of the WHO CC are:

- To utilize existing research facilities at the University of Toronto for research and policy analysis and training on issues related to the pharmaceutical component of health systems anti-corruption, transparency, and accountability (ACTA) in collaboration with the WHO.
- To bolster the global dissemination of knowledge on issues related to the pharmaceutical component of health systems ACTA.
- To support collaboration and help intensify the work of the WHO with respect to the pharmaceutical component of healthy systems ACTA.

This past year, once again, the WHO CC Fellows produced tremendous knowledge on ACTA issues as the report highlights. The WHO CC also continued its commitment to disseminating knowledge through online webinars, research seminars, and virtual workshops which has allowed us to reach a wider audience and strengthen our virtual community and global reach. We hosted numerous webinars that featured fellows, international and national speakers and were centered around a variety of subjects including corruption risks in the deployment of COVID-19 vaccines, the opioid crisis and understanding compliance risks within the pharmaceutical industry, as well as a workshop on Governance, Leadership and Transparency in Pharmaceutical Sector Procurement for the EAC Regional Centre of Excellence for Vaccines, Immunisation and Health Supply Chain Management in Rwanda.

The COVID-19 pandemic has exacerbated inequity in access to healthcare and also squarely showed how vital transparency and accountability in pharmaceutical systems is if we hope to have robust, equitable health systems globally. We continue to be invested in these topics and to foster discourse and research in these areas. I would like to extend my gratitude to the WHO CC Fellows for their unwavering commitment to our objectives. Finally, thank you to the Connaught Global Challenge Award for supporting many of our projects.

Jillian Clare Kohler PhD
Director
WHO Collaborating Centre for Governance, Transparency
& Accountability in the Pharmaceutical Sector

Webinars

The Centre held 7 collaborative webinars featuring international and national experts.

November 11, 2021

Webinar: Corruption Risks in the Deployment of COVID-19 Vaccines: A Clear and Present Threat to Global Public Health

Presenter: Kohler, J. C.

Details: Dr. Kohler is a Professor at the Leslie Dan Faculty of Pharmacy, Dalla Lana School of Public Health, and Munk School of Global Affairs and Public Policy at the University of Toronto. She is also the Director of the WHO Collaborating Centre for Governance, Transparency and Accountability in the Pharmaceutical Sector.

December 7, 2021

Webinar: Corrupting Health Care: The Unequal-by-Design COVID-19 Global Vaccination

Presenter: Benavides, X.

Details: Ximena Benavides is a Lecturer in Critical Thinking at Yale University. She is a Fellow at the Yale Institute for Global Health (with GAVI-COVAX), the Yale Law School's Information Society Project, and the Yale Fox International Program at UBC.

January 24, 2022

Webinar: Infodemiology, the Infodemic, and Combating Misinformation during the COVID-19 Pandemic

Presenter: Mackey, T. K.

Details: Dr. Mackey is a Professor at UC San Diego in the Global Health Program, the Director of the Global Health Policy and Data Institute, the Editor-in-Chief of JMIR Infodemiology, a faculty affiliate at the San Diego Supercomputer Center, and is also the CEO and co-founder of the National Institutes of Health funded startup S-3 Research. He has co-authored over 200 articles in a wide array of interdisciplinary journals with a focus on topics in global health, health policy, global health governance, pharmaceutical policy, public health and data science, and infodemiology. He has also acted as a past consultant for the World Health Organization, U.S. Department of Justice and several other organizations.

May 2, 2022

Webinar: Empire Of Pain: The Sackler Family, Purdue Pharma and the Opioid Crisis

Presenter: Keefe, P. R.

Details: Patrick Radden Keefe is a long-time staff writer at The New Yorker and author of the international bestsellers *Empire of Pain: The Secret History of the Sackler Dynasty*, which was awarded the Baillie Gifford Prize for Nonfiction, and *Say Nothing: A True Story of Murder and Memory in Northern Ireland*, which received the National Book Critics Circle Award and the Orwell Prize for Political Writing. He is also the creator and host of the 8-part podcast "Wind of Change," which The Guardian named the #1 podcast of 2020. His new book, *Rogues: True Stories of Grifters, Killers, Rebels and Crooks* will be published in June.

June 13-17, 2022

Training Seminar: Governance, Leadership and Transparency in Pharmaceutical Sector Procurement in the East Africa Community Countries

Presenters: Kohler, J. C.

Details: The aim of the five-day trainings was to ensure that selected participants from the EAC Medical Procurement Department, medical stores, and the National Vaccines Programme are:

- Familiar with various issues in governance, transparency and accountability in the pharmaceutical sector in their respective institutions in the EAC;
- Able to develop strategies for increasing governance, transparency and accountability in the process of selecting and procuring medicines in their respective countries;
- Able to deliver best practices for improving systems of leadership and accountability through coordination and collaboration among strategic partners;
- Able to provide immediate impact to their organizations through learnings gained from applied, real-world case studies and from colleagues working in similar situations.

June 28, 2022

Webinar: Understanding Compliance Risks within the Pharmaceutical Industry

Presenters: Proudley, G., **Kohler, J. C.**, Rubio, E., Humphrey E.

Details: Gavin Proudley, Head of Third Party Risk Proposition at Dow Jones Risk & Compliance; Dr Jillian Kohler, Professor at the Leslie Dan Faculty of Pharmacy; Emilio Rubio Ph.D, Head of Ethics, Risk and Compliance at Sandoz; Elizabeth Humphrey, Financial Crime Researcher at Themis

October 13, 2022

Webinar: Privacy Implications of Direct-to-Patient Commercial Virtual Care

Presenter: Spithoff, S.

Details: Dr. Sheryl Spithoff is an Assistant professor in the Department of Family and Community Medicine at the University of Toronto, and a staff physician at Women's College Hospital. In this seminar, she will present research findings from her research team's study examining the privacy-related ethical implications of Canada's direct-to-patient commercial virtual care industry. Commercial virtual care expanded with the Covid-19 pandemic, providing rapid access to medical services. Through analysis of interview data and privacy policy documents, her research team concluded that commercial virtual care in Canada enables widespread commercial use of health data, permits patient surveillance, and presents risks to privacy and autonomy. These risks may disproportionately affect structurally marginalized groups and communities.

Presentations, Lectures, and Panels

Cadarette, Suzanne

August, 2022

International Conference on Pharmacoepidemiology and Therapeutic Risk Management

Rzepka A. M., Gomes T., Cheung A. M., Kim S., Chaudhry M., **Cadarette S. M.** Impact of the COVID-19 pandemic on timeliness of denosumab dispensations [abstract]

August, 2022

International Conference on Pharmacoepidemiology and Therapeutic Risk Management

Konstantelos N., Rzepka A. M., Burden A. M., Cheung A. M., Kim S., **Grootendorst P., Cadarette, S. M.** Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review [abstract]

September, 2022

American Society for Bone and Mineral Research Annual Meeting

Rzepka A. M., Gomes T., Cheung A. M., Kim S., Chaudhry M., **Cadarette S. M.** “Impact of the COVID-19 pandemic on timeliness of denosumab dispensations [abstract]”

September, 2022

American Society for Bone and Mineral Research Annual Meeting

Konstantelos N., Rzepka A. M., Burden A. M., Cheung A. M., Kim S., **Grootendorst P., Cadarette SM.** Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review [abstract]

Di Ruggiero, Erica

March 23, 2022

Le Centre de collaboration nationale sur les politiques publiques et la santé

Di Ruggiero, E., Clavier, C., Denis J. L. « La gouvernance des systèmes de santé publique : mieux la connaître et l'actionner pour renforcer les systèmes de santé publique au Canada »

March 29, 2022

National Collaborating Centre for Healthy Public Health Policy Webinar

Di Ruggiero, E., Denis, J. L., Hunter, D. “Public Health Systems Governance: Better Understanding and Acting on Governance to Strengthen Public Health Systems in Canada”

June 15, 2022

Canadian Public Health Association Conference (virtual)

Di Ruggiero, E., Fafard, P., Guyon, A. “Governance options to strengthen public health systems”

Gagnon, Marc-Andre

November 9, 2021

University of Ottawa

Lecture in graduate course in health law

Gagnon, M. A., Jackman, M. Co-lecturer, « Réduire le coût des médicaments en adoptant un régime public entièrement financé par l'État »

November 12, 2021

Carleton University

School of Public Policy and Administration's Open House

Gagnon, M. A. Presenter, “Pandemics and Public Policy”

November 12, 2021

Le Réseau québécois pour une mondialisation inclusive (RQMI) en collaboration avec l'Association Québécoise des Organisations en Coopération Internationale (AQOCI)

Les Journées québécoises de la solidarité internationale

Gagnon, M. A. Webinaire, « Pour un accès gratuit et universel aux vaccins anti-coronavirus »

November 18, 2021

University of Toronto

Drug Safety and Effectiveness Cross-Disciplinary Training

Gagnon, M. A. Webinar, “Financing the Public Provision of Prescription Drugs in Canada; Comparison and Assessment of Financing Options”

November 24, 2021

OECD Roundtable on Price Transparency (Paris)

Gagnon, M. A. Presenter, “Exploring the feasibility of sharing drug price information across countries”

January 27, 2022

Les Rencontres-Débats Prescrire 2022 (Paris)

Gagnon, M. A. Présentation, « Après covid-19, de quelles firmes pharmaceutiques avons-nous besoin? »

<https://www.prescrire.org/Fr/1253/3086/63861/8002/SubReportList.aspx>

March 3, 2022

Carleton University

Lecture in graduate course in Policy Analysis

Gagnon M. A., Varughese, A. Co-lecturer, “The Battle for Universal Pharmacare”

April 27, 2022

Carleton University, FPA Research Series

Symposium Analyzing Ghost-Management: Dynamics of Corporate Power in a Risk Society

Gagnon, M. A. Presenter, “The political economy of Ghost-Management: Introduction to a New Research Project”

April 29, 2022

Carleton University, FPA Research Series

Symposium Analyzing Ghost-Management: Dynamics of Corporate Power in a Risk Society

Gagnon, M. A., Dong, M. Co-presenter, “Scoping Literature Review of Peer-reviewed Journal Articles Using Internal Company Documents for Pharmaceutical Industry Research”

May 6, 2022

Health Canada

Briefing on Universal Pharmacare

Gagnon, M. A. Discussion, “The role for the Canadian Drug Agency”

May 9, 2022

House of Commons, Government of Canada

Testimony for the Standing Committee on Foreign Affairs (FAAE)

Gagnon, M. A. Presenter, “Vaccine Equity and Intellectual Property Rights”

<https://www.ourcommons.ca/DocumentViewer/en/44-1/FAAE/meeting-19/notice>

August 16, 2022

Minister of Health and Members of the Academic Community

Gagnon, M. A. Roundtable, “Advancing National Pharmaceutical Initiatives”

September 13, 2022

Health Canada

Briefing on Pharmaceutical Policy

Gagnon, M. A. Discussion, “The role for the Canadian Drug Agency for a National strategy for rare diseases”

Grundy, Quinn

March 30, 2022

Joint Centre for Bioethics Seminar Series, University of Toronto [livestreamed]

Grundy, Q. Invited speaker (with Dr Daniel Buchman), “Canadian Big Cannabis companies and the financial sponsorship of scientific research”

June 14, 2022

Joint Learning Network (JLN), USAID Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program

Grundy, Q. Keynote presentation at the first 3 workshops, “Conflict of interest and public sector pharmaceutical committees”

October 4, 2022

World Health Organization and the USAID Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program

Online Information Session: Managing conflicts of interest in national pharmaceutical systems

Grundy, Q. Invited speaker, “Research on conflict-of-interest policy in public pharmaceutical systems in the South East Asia Region”

October 17, 2022

Canadian Association for Population Therapeutics 2022 Annual Conference in Toronto, Canada

Grundy, Q. Poster presentation, “Mapping the extent, nature, and range of pharmaceutical industry patient support programs in Canada”

Kohler, Jillian C.

October, 2021

University of Toronto, Faculty of Law

Kohler, J. C. “Corruption Risks in COVID-19 A Clear and Present Danger”

October, 2021

Faculty of Medicine, Pain Institute

Kohler, J. C. “Conflict of Interest in the Pharmaceutical System”

October, 2021

Faculty of Medicine

Kohler, J. C. “There are No Free Lunches: COI as Gateway to Corruption”

November, 2021

UNDP

Sustainable Production in the Health Sector Global Forum

Kohler, J. C. Session, “Business integrity and Transparency for Ethical Health Supply Chains, Corruption Risks in Medical Products Procurement”

November 24, 2021

Canadian Conference on Global Health

Gorodensky, A., **Kohler, J.C., Grundy, Q., Persaud, N.** “Equity Issues in the Distribution of COVID-19 Vaccines Globally”

November 24, 2021

Canadian Conference on Global Health

Kohler, J. C. “COVID-19 Vaccines and Corruption Risks: Preventing Corruption in the Manufacture, Allocation and Distribution of Vaccines”

November 24, 2021

Canadian Conference on Global Health

Kohler, J. C. Gorodensky, A., Bowra, A. “Anti-Corruption in International Organizations: An Exploration of the Risks and Responses During COVID-19”

December, 2021

UNDP – Istanbul

Kohler, J. C. “Corruption Risks in East Europe and Central Asia During COVID”

March, 2022

Consortium of Universities for Global Health

Bowra, A., Gorodensky, A., Saeed, G., & **Kohler, J. C.** “Combating Corruption in Health Systems: An Exploration of Anti-Corruption Efforts by the World Health Organization, the Global Fund, the World Bank Group, and the United Nations Development Programme”

September 16, 2022

Annual American Political Science Association Meeting, Montreal, Canada

Grundy, Q., Kohler, J. C. Paper presentation, “The Need for Shared Health Governance, Mutual Collective Accountability, and Transparency in COVAX”

Lemmens, Trudo

February 10, 2022

WHO Regional Office for Europe

Solidarity and social contracts in the context of the UN Sustainable Development Goals (SDGs) Webinar

Lemmens, T. “Social Contract and Human Rights Obligations in the Context of High-Priced Medicines”

September 1, 2022

Oslo Medicines Initiative (OMI)

Lemmens, T. “Launch of the OMI technical report series – webinar”

Lexchin, Joel

January, 2022

University of Toronto, Centre for Global Health, Dalla Lana School of Public Health

Health Inc.: Corporations, capitalism and commercial determinants of health seminar series

Lexchin, J. “What do drug companies say when their drugs are removed for safety reasons”

August, 2022

Osgoode Hall Law School

LAW 6859 Pharmaceutical Regulation

Lexchin, J. Lecture, “(Non)transparency in Health Canada’s Pharmaceutical Regulation”

September, 2022

Doctors for America National Leadership Conference

Lexchin, J. “Too Many Cooks in the Kitchen: Consultants, Medical Societies and Conflict of Interest in FDA Regulatory Review”

Mackey, Tim K.

October 25, 2021

American Public Health Association Annual Meeting [virtual]

Mackey, T. K. Oral presenter, “Leveraging social media and data science to generate insights into health equity topics: Case studies and lessons learned”

October 26, 2021

American Public Health Association Annual Meeting [virtual]

Mackey, T. K. Oral presenter, “Building an interdisciplinary research community to tackle the COVID-19 infodemic and beyond”

November 11, 2021

National Association of Drug Diversion Investigators 32nd Annual Conference

Mackey, T. K. “AI Can Help Find Illegal Opioid Sellers Online; Wildlife Traffickers; and Counterfeits”

November 19, 2021

Duke Margolis Center for Health Policy

Mackey, T. K. Virtual public workshop, “Prescription Drug Promotion in the Digital Space”

December 9, 2021

San Diego Supercomputer Center

Mackey, T. K. Virtual panel, “Advancements in Global Health Policy and Data Analytics”

2022

IQVIA Institute

Mackey, T. K. Invited participant, “Illegal Online Pharmacies Roundtable”

January 20, 2022

International Narcotics Control Board, Expert Group Meeting

Mackey, T. K. Virtual meeting, “Generating Public Health Intelligence to Detect and Characterize Illicit Opioid and Related Dangerous Substances through Social Media”

March 7, 2022

South Dakota School of Mines and Technology, Center for Understanding & Disrupting the Illicit Economy

Mackey, T. K. Online seminar, “Multidisciplinary Approaches to Combat the Illicit Economy on Social Media Platforms: A Review of Use Cases”

May 16, 2022

Michigan State University, Center for Anti-Counterfeiting and Product Protection

A-CAPP Academic Hot Topics

Mackey T. K. Online seminar, “Latest Trends on the Detection of Illegal Online Sales of Controlled Substances”

June 8, 2022

SDSC Data East Conference

Mackey, T. K. Invited speaker for online panel, “Are Data Privacy and Security Innovations in Healthcare Translational, or Unique to Healthcare and Health Sciences?”

June 17, 2022

American College of Preventive Medicine Annual Conference, Denver, Colorado

Mackey, T. K. Invited speaker for plenary session, “Communications for Evidence-based Impact”

Persaud, Nav

N.D.

United States Senate

Persaud, N. Invited Presenter, “Why Does the U.S. pay the Highest Prices in the World for Prescription Drugs?”

December 8, 2021

University of British Columbia

Persaud, N. Invited Speaker, “Best Evidence Webinar: Which Medicines are Essential in Canada?”

June 7, 2022

Royal College of Surgeons in Ireland

Persaud, N. Presenter, “National essential medicines lists”

Vian, Taryn

October 25, 2021

University of San Francisco Orange County Campus

MPH 627 Advanced Topics in Epidemiology

Vian, T. Guest Lecturer, “Corruption and Vaccines”

June 7-28 and August 18, 2022

Joint Learning Network (JLN) for Universal Health Coverage

Managing Conflicts of Interest in National Pharmaceutical Systems Virtual Learning Exchange

Vian, T. Speaker and Facilitator, “Processes and Procedures for Conflict of interest Prevention and Management”

October 4, 2022

WHO Webinar on Managing Conflicts of Interest in National Pharmaceutical Systems

Vian, T. Facilitator, “Introduction to Conflicts of Interest”

Publications

Cadarette, Susan

Konstantelos, N., Rzepka, A. M., Burden, A. M., Cheung, A. M., Kim, S., **Grootendorst, P.**, & **Cadarette, S. M.** (2022). Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*, 33(9), 1837–1844. <https://doi.org/10.1007/s00198-022-06395-x>

Di Ruggiero, Erica

Kickbusch, I., Behrendt, T., **Di Ruggiero, E.**, Gong J. Karaman, E., Michaelides, O., Watulo, F. (2022, June 27). *Global health diplomacy*. Oxford Bibliographies. Retrieved from <https://www.oxfordbibliographies.com/view/document/obo-9780199756797/obo-9780199756797-0101.xml>

Di Ruggiero, E., Bhatia, D., Umar, I., Arpin, E., Champagne, C., Clavier, C., Denis, J-L., & Hunter, D. (2022). Governing for the Public’s Health: Governance Options for a Strengthened and Renewed Public Health System in Canada. National Collaborating Centres for Public Health.

Bhatia, D., Mishra, S., Kirubarajan, A., Yanful, B., Allin, S., & **Di Ruggiero, E.** (2021). Identifying priorities for research on financial risk protection to achieve Universal Health Coverage: A scoping overview of reviews. *BMJ Open*, 12(3). <https://doi.org/10.1136/bmjopen-2021-052041>

Gagnon, Marc-Andre

Gagnon, M. A. (2022, May 3). *Pensons-y Avant de Rejeter une assurance médicaments Publique Universelle*. Le Devoir. Retrieved from <https://www.ledevoir.com/opinion/idees/706356/idees-pensons-y-avant-de-rejeter-une-assurance-medicaments-publique-universelle>

Gagnon, M. A. (2022, February 7). *Pharmacare in Canada: One step forward, Two steps back*. The Hill Times. Retrieved from <https://www.hilltimes.com/2022/02/07/pharmacare-in-canada-one-step-forward-two-steps-back/341955>

Gagnon, M. A. (2021). La Canada face à l'iniquité vaccinale globale : se situer du mauvais côté de l'histoire. *Revue Interventions économiques*, Hors-série. <https://doi.org/10.4000/interventionseconomiques.14794>

Grootendorst, Paul

Grootendorst, P., Moradpour, J., Schunk, M., & Van Exan, R. (2022, May 3). *Home remedies: How should Canada acquire vaccines for the next pandemic?* Home Remedies: How Should Canada Acquire Vaccines for the Next Pandemic? | C.D. Howe Institute | Canada Economy News | Canadian Government Policy. Retrieved from <https://www.cdhowe.org/public-policy-research/home-remedies-how-should-canada-acquire-vaccines-next-pandemic-0>

Grootendorst, P. (2022). How should Canada ensure access to vaccines for the next pandemic. *On Track: Conference of Defense Association Institute*, 27, 27-31. <https://cdainstitute.ca/wp-content/uploads/2022/02/On-Track-27-Small-file.pdf>

Grootendorst, P., & Moradpour, J. (2022, May 11). *Opinion: Vaccines for the next pandemic: Connaught 2.0 is not the answer*. National Post epaper. Retrieved from <https://epaper.nationalpost.com/article/282007560983723>

Spicer, O., & **Grootendorst, P.** (2022). The effect of patented drug price on the share of new medicines across OECD countries. *Health policy (Amsterdam, Netherlands)*, 126(8), 795–801. <https://doi.org/10.1016/j.healthpol.2022.05.003>

Grundy, Quinn

Grundy, Q., Davenport Huyer, L., Parker, L. & Bero, L. (2022). Branded care: The policy implications of pharmaceutical industry-funded nursing care related to specialty medicines. *Policy, Politics, and Nursing Practice*. doi: 10.1177/15271544221121749 [PA; contribution: conceptualization, study design, supervision, secondary analysis, drafting of manuscript; impact factor=0.85]

Grundy, Q. & Parker, L. (2022). *Conflict of interest management policies and practices in the public pharmaceutical sector in South-East Asia Region*. New Delhi, India: World Health Organization South-East Asia Region Office (SEARO). Available at: <https://www.who.int/southeastasia/internal-publications-detail/conflict-of-interest-management-policies-and-practices-in-the-public-pharmaceutical-sector-in-the>

[who-south-east-asia-region](#) (Dimancesco, D., Tisocki, K., Kim, U., Fusire, T. T., Walkowiak, H., Shridhar, M., Kohler, J., & Vian, T., Advisors)

Sud, A., Strang, M., Buchman, D., **Spithoff, S.**, Webster, F., Upshur, R. & **Grundy, Q.** (2022). Dispensing education: Pharmaceutical industry promotion of Suboxone® during the opioid crisis. *BMJ Open*, 12(7): e059561. [SA; contribution: supervision, conceptualization, study design, data collection, data analysis, critical revision of manuscript; impact factor=2.692]

Grundy, Q., Millington, A., Robinson, A., Held, F. & Fabbri, A. (2022). Exposure, access and interaction: A global analysis of sponsorship of nursing professional associations. *J Advanced Nursing*, 78(4), 1140-1153. doi: 10.1111/jan.15158. [PA; contribution: acquisition of funding, study design, data collection, data analysis, supervision, drafting of the manuscript; impact factor = 3.187]

Kohler, Jillian C.

Bowra, A., Saeed, G., Gorodensky, A., & **Kohler, J. C.** (2022). An exploration of anti-corruption and health in international organizations. *PloS one*, 17(8), e0269203. <https://doi.org/10.1371/journal.pone.0269203>

Saeed, G., **Kohler, J. C.**, Cuomo, R. E., & **Mackey, T. K.** (2022). A systematic review of digital technology and innovation and its potential to address anti-corruption, transparency, and accountability in the pharmaceutical supply chain. *Expert opinion on drug safety*, 21(8), 1061–1088. <https://doi.org/10.1080/14740338.2022.2091543>

Saeed, G. A., **Kohler J. C.**, & **Vian, T.** (2022). Corruption Risks within Pharmaceutical Systems. In *Encyclopedia of Corruption Law*. chapter, Edward Elgar Publishing Co.

Gorodensky, A., & **Kohler, J. C.** (2022). State capture through indemnification demands? Effects on equity in the global distribution of COVID-19 vaccines. *Journal of pharmaceutical policy and practice*, 15(1), 50. <https://doi.org/10.1186/s40545-022-00442-y>

Lemmens, Trudo

Lemmens, T., Ghimire, K. M., **Perehudoff, K.**, & **Persaud, N.** (2022). *The social contract and human rights bases for promoting access to effective, novel, high-priced medicines* (ISBN: 978-92-890-5826-1). Oslo Medicines Initiative (OMI). <https://www.who.int/europe/publications/i/item/9789289058261>

Bardosh, K., de Figueiredo, A., Gur-Arie, R., Jamrozik, E., Doidge, J., **Lemmens, T.**, Keshavjee, S., Graham, J. E., & Baral, S. (2022). The unintended consequences of covid-19 vaccine policy: Why mandates, passports and restrictions may cause more harm than good. *BMJ Global Health*, 7(5). <https://doi.org/10.1136/bmjgh-2022-008684>

Lexchin, Joel

Klein, D. E., & **Lexchin, J.** (2022, July 7). *\$150M is not enough: Canada's proposed Purdue Pharma Settlement for opioid damages is paltry and won't prevent future crises*. The Conversation. Retrieved

October 5, 2022, from <https://theconversation.com/150m-is-not-enough-canadas-proposed-purdue-pharma-settlement-for-opioid-damages-is-paltry-and-wont-prevent-future-crises-186361>

Mintzes, B., Bhasale, A., Torka, M., Lopert, R., Pearson, S. A., **Lexchin, J.**, & Bero, L. (2021). A sorry tale of unnecessary secrecy about medicine safety. *Internal medicine journal*, 51(10), 1765–1766. <https://doi.org/10.1111/imj.15513>

Lexchin J. (2021). Companies' statements about drugs withdrawn from the Canadian market: A descriptive analysis. *The International journal of risk & safety in medicine*, 32(4), 331–341. <https://doi.org/10.3233/JRS-210013>

Lexchin J. (2022). COVID-19 Vaccine Task Force and Conflicts of Interest. *Healthcare policy = Politiques de sante*, 17(3), 20–27. <https://doi.org/10.12927/hcpol.2022.26732>

Lexchin J. (2021). Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada. *International journal of health policy and management*, 10.34172/ijhpm.2021.172. Advance online publication. <https://doi.org/10.34172/ijhpm.2021.172>

Lexchin, J. (2021, November 30). *Drug companies protest when Health Canada withdraws their products for safety reasons*. The Conversation. Retrieved October 5, 2022, from <https://theconversation.com/drug-companies-protest-when-health-canada-withdraws-their-products-for-safety-reasons-172835>

Abi-Jaoude, E., & **Lexchin, J.** (2021). Health Canada: optimizing transparency and its impact for patients. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, 193(38), E1503. <https://doi.org/10.1503/cmaj.80084>

Lee, S. K., Mahl, S. K., Rowe, B. H., & **Lexchin, J.** (2022). Pharmaceutical security for Canada. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, 194(32), E1113–E1116. <https://doi.org/10.1503/cmaj.220324>

Lexchin, J. (2022, July 20). *Less talk, more action needed to reform IP for all*. 360info. Retrieved October 5, 2022, from <https://360info.org/less-talk-more-action-needed-to-reform-ip-for-all/>

Lexchin, J. (2022, May 12). *Medical Societies and health-care companies may be too close for comfort*. The Conversation. Retrieved October 5, 2022, from <https://theconversation.com/medical-societies-and-health-care-companies-may-be-too-close-for-comfort-182927>

Lexchin, J. (2022). Pharmaceutical company payments to healthcare professionals and healthcare organizations in Canada: An observational study. *Healthcare Policy | Politiques De Santé*, 17(3), 42–48. <https://doi.org/10.12927/hcpol.2022.26729>

Lexchin J. (2022). Reforms to the patented medicine prices review board and the introduction of new drugs in Canada: An observational study. *Health policy (Amsterdam, Netherlands)*, 126(10), 1018–1022. <https://doi.org/10.1016/j.healthpol.2022.08.006>

Lexchin, J. (2022). Relationship Between the Canadian Government and Big Pharma — “Clientele Pluralism.” In *Corporate rules: The real world of business regulation in Canada* (pp. 111–127). chapter, James Lorimer and Company.

Lexchin J. (2022). Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study. *JRSM open*, 13(7), 20542704221111243.
<https://doi.org/10.1177/20542704221111243>

Lexchin J. (2022). Sponsorship of Canadian Professional Medical Societies by Drug, Medical Device and Medical Technology Companies: a Cross-sectional Study. *Journal of general internal medicine*, 10.1007/s11606-022-07623-0. Advance online publication. <https://doi.org/10.1007/s11606-022-07623-0>

Lexchin, J. (2022, April 25). *The Federal Government Caves into big pharma on drug prices*. National Newswatch. Retrieved October 5, 2022, from <https://www.nationalnewswatch.com/2022/04/25/the-federal-government-caves-into-big-pharma-on-drug-prices/#.YmaqyC8r19h>

Lexchin J. (2022). Use of priority and provisional approval pathways by the Australian Therapeutic Goods Administration in approving new medicines: a cross-sectional study. *Australian health review : a publication of the Australian Hospital Association*, 46(3), 309–315. <https://doi.org/10.1071/AH22008>

Lexchin, J., Batt, S., Goldberg, D., & Shnier, A. (2022). National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study. *BMJ open*, 12(3), e055287. <https://doi.org/10.1136/bmjopen-2021-055287>

Mackey, Tim K.

Ahmed, J., Modica de Mohac, L., **Mackey, T. K.**, & Raimi-Abraham, B. T. (2022). A critical review on the availability of substandard and falsified medicines online: Incidence, challenges and perspectives. *The Journal of Medicine Access*, 6, 239920262210745. <https://doi.org/10.1177/23992026221074548>

Shah, N., Nali, M., Bardier, C., Li, J., Maroulis, J., Cuomo, R., & **Mackey, T. K.** (2021). Applying topic modelling and qualitative content analysis to identify and characterise ENDS product promotion and sales on Instagram. *Tobacco control*, tobaccocontrol-2021-056937. Advance online publication. <https://doi.org/10.1136/tobaccocontrol-2021-056937>

Purushothaman, V., McMann, T. J., Li, Z., Cuomo, R. E., & **Mackey, T. K.** (2022). Content and trend analysis of user-generated nicotine sickness tweets: A retrospective infoveillance study. *Tobacco induced diseases*, 20, 30. <https://doi.org/10.18332/tid/145941>

Calac, A. J., Haupt, M. R., Li, Z., & **Mackey, T.** (2022). Spread of COVID-19 Vaccine Misinformation in the Ninth Inning: Retrospective Observational Infodemic Study. *JMIR infodemiology*, 2(1), e33587. <https://doi.org/10.2196/33587>

McMann, T. J., Calac, A., Nali, M., Cuomo, R., Maroulis, J., & **Mackey, T. K.** (2022). Synthetic cannabinoids in prisons: Content analysis of tiktoks. *JMIR Infodemiology*, 2(1). <https://doi.org/10.2196/37632>

Haupt, M. R., Cuomo, R., Li, J., Nali, M., & **Mackey, T. K.** (2022). The influence of social media affordances on drug dealer posting behavior across multiple social networking sites (SNS). *Computers in Human Behavior Reports*, 8, 100235. <https://doi.org/10.1016/j.chbr.2022.100235>

McGahan, Anita

Ahmed, A., Hounsell, K. G., Sadiq, T., Naguib, M., Koswin, K., Dharmawansa, C., Rasan, T., & **McGahan, A. M.** (2021). Eliminating malaria in conflict zones: public health strategies developed in the Sri Lanka Civil War. *BMJ global health*, 6(12), e007453. <https://doi.org/10.1136/bmjgh-2021-007453>

Bellatin, A., Hyder, A., Rao, S., Zhang, P. C., & **McGahan, A. M.** (2021). Overcoming vaccine deployment challenges among the hardest to reach: lessons from polio elimination in India. *BMJ global health*, 6(4), e005125. <https://doi.org/10.1136/bmjgh-2021-005125>

Distelhorst, G., & **McGahan, A.** (2021). Socially irresponsible employment in emerging-market manufacturers. *Organization Science*. <https://doi.org/10.1287/orsc.2021.1526>

Hofstetter, J. S., **McGahan, A. M.**, Silverman, B. S., & Zoogah, B. D. (2022). Sustainability and global value chains in Africa: Introduction to the special issue. *Africa Journal of Management*, 8(1), 1–14. <https://doi.org/10.1080/23322373.2021.2018220>

Perehudoff, Katrina

Perehudoff, K., 't Hoen, E., Mara, K., Balasubramaniam, T., Abbott, F., Baker, B., Boulet, P., Kamal-Yanni, M., Martin, M., Munoz Tellez, V., Natsis, Y., Ortún-Rubio, V., Rathod, S., Torrent, M., Vawda, Y., Villarroel, L., & Love, J. (2022). A pandemic treaty for equitable global access to medical countermeasures: seven recommendations for sharing intellectual property, know-how and technology. *BMJ global health*, 7(7), e009709. <https://doi.org/10.1136/bmjgh-2022-009709>

Perehudoff K. (2022). European governments should align medicines pricing practices with global transparency norms and legal principles. *The Lancet regional health. Europe*, 16, 100375. <https://doi.org/10.1016/j.lanepe.2022.100375>

Persaud, Nav

Adekoya, I., Maraj, D., Steiner, L., Yaphe, H., Moja, L., Magrini, N., Cooke, G., Loeb, M., & **Persaud, N.** (2021). Comparison of antibiotics included in National Essential Medicines Lists of 138 countries using the who access, watch, reserve (AWARE) classification: A cross-sectional study. *The Lancet Infectious Diseases*, 21(10), 1429–1440. [https://doi.org/10.1016/s1473-3099\(20\)30854-9](https://doi.org/10.1016/s1473-3099(20)30854-9)

Kraus, R., Yeung, R. S. M., & **Persaud, N.** (2021). Biologic medicine inclusion in 138 national essential medicines lists. *Pediatric rheumatology online journal*, 19(1), 140. <https://doi.org/10.1186/s12969-021-00608-z>

Maraj, D., Steiner, L., & **Persaud, N.** (2022). Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list. *Journal of clinical tuberculosis and other mycobacterial diseases*, 27, 100305. <https://doi.org/10.1016/j.jctube.2022.100305>

Persaud, N. (2022). In *Transparency, Power and Influence in the Pharmaceutical Industry*. chapter, University of Toronto Press.

Persaud, N., Bedard, M., Boozary, A., Glazier, R. H., Gomes, T., Hwang, S. W., Juni, P., Law, M. R., Mamdani, M., Manns, B., Martin, D., Morgan, S. G., Oh, P., Pinto, A. D., Shah, B. R., Sullivan, F., Umali, N., Thorpe, K. E., Tu, K., Laupacis, A., CLEAN Meds. (2021). Adherence at 2 years with distribution of essential medicines at no charge: The CLEAN Meds randomized clinical trial. *PLoS medicine*, 18(5), e1003590. <https://doi.org/10.1371/journal.pmed.1003590>

Piggott, T., Nowak, A., Brignardello-Petersen, R., Cooke, G. S., Huttner, B., Schünemann, H. J., **Persaud, N.**, Magrini, N., & Moja, L. (2022). Global Status of Essential Medicine Selection: A systematic comparison of National Essential Medicine lists with recommendations by WHO. *BMJ Open*, 12(2). <https://doi.org/10.1136/bmjopen-2021-053349>

Spithoff, S., Stockdale, J., Rowe, R., McPhail, B., & **Persaud, N.** (2022). The commercialization of patient data in Canada: ethics, privacy and policy. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*, 194(3), E95–E97. <https://doi.org/10.1503/cmaj.210455>

Tadrous, Mina

Schneider, T., Gomes, T., Hayes, K. N., Suda, K. J., & **Tadrous, M.** (2022). Comparisons of Insulin Spending and Price Between Canada and the United States. *Mayo Clinic proceedings*, 97(3), 573–578. <https://doi.org/10.1016/j.mayocp.2021.11.028>

Zeitouny, S., Suda, K. J., Mitsantisuk, K., Law, M. R., & **Tadrous, M.** (2021). Mapping global trends in vaccine sales before and during the first wave of the COVID-19 pandemic: A cross-sectional time-series analysis. *BMJ Global Health*, 6(12). <https://doi.org/10.1136/bmjgh-2021-006874>

Suda, K. J., Kim, K. C., Hernandez, I., Gellad, W. F., Rothenberger, S., Campbell, A., Malliart, L., & **Tadrous, M.** (2022). The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis. *Journal of the American Pharmacists Association : JAPhA*, 62(3), 766–774.e6. <https://doi.org/10.1016/j.japh.2021.12.014>

Hofmeister, M., Sivakumar, A., Clement, F., Hayes, K. N., Law, M., Guertin, J. R., Neville, H. L., & **Tadrous, M.** (2022). Trends in Canadian prescription drug purchasing: 2001-2020. *Journal of pharmaceutical policy and practice*, 15(1), 20. <https://doi.org/10.1186/s40545-022-00420-4>

Thompson, Alison

Thompson, A. (2021). The Paradox of Vaccine Hesitancy and Refusal: Public Health and the Moral Work of Motherhood. In *Living Pharmaceutical lives*. essay, Routledge.

Vian, Tian

Quah, S. R., Cockerham, W. C., **Vian, T.**, & Crable, E. (2022). Corruption and the Consequences for Public Health. In *International Encyclopedia of Public Health*. section, Elsevier AP.

Walkowiak, H., Dimancesco, D., Bero, L., & **Vian, T.** (2022, September 22). *Managing conflicts of interest, a how-to guide for public pharmaceutical-sector committees in low- and middle-income countries*. World Health Organization. Retrieved from <https://www.who.int/publications/i/item/9789240057982>

Vian, T., Agnew, B., & McInnes, K. (2021, October 6). *Whistleblowing as an anti-corruption strategy in health and pharmaceutical organizations: A scoping review protocol*. OSF. Retrieved from <https://osf.io/bpa5f/>

Vian, T., Agnew, B., & McInnes, K. (2022). Whistleblowing as an anti-corruption strategy in health and pharmaceutical organizations in low- and middle-income countries: a scoping review. *Global health action*, 15(1), 2140494. <https://doi.org/10.1080/16549716.2022.2140494>

Media Mentions, Appearances, and Interviews

Kohler, Jillian C.

October 26, 2021

Kohler, J. C. Interview in CBC News

Beattie, A. *He's had 3 COVID-19 shots. So why does he have to isolate before seeing his Canadian grandkids?*

Available at: <https://www.cbc.ca/news/canada/toronto/he-s-had-3-covid-19-shots-so-why-does-he-have-to-isolate-before-seeing-his-canadian-grandkids-1.6223919>

November 30, 2021

Kohler, J. C. Interview in the Financial Times

Kuchler, H., Mancini D. P., Pilling D. *The inside story of the Pfizer vaccine: 'a once-in-an-epoch windfall'*

Available at: <https://www.ft.com/content/0cea5e3f-d4c4-4ee2-961a-3aa150f388ec>

July 8, 2022

Kohler, J. C. Interview in Global News

Hill, B., Sahota, R. *ArriveCAN 2.0: Ottawa confirms controversial app will outlast pandemic.*

Available at: <https://globalnews.ca/news/8972840/arrivecan-2-0-border-app-here-to-stay/>

Mackey, Tim K.

February 17, 2022

Mackey, T. K. Podcast Interview in Phil in the Blanks

“Fentanyl Crisis”

Available at: <https://www.youtube.com/watch?v=HDWEwaB7d3w>

March 8, 2022

Mackey, T. K. TV Appearance, Interview, and Research Coverage in Dr. Phil Show
“*Experts Explain How People Are Lacing Counterfeit Pills with Fentanyl*”

Available at: <https://www.youtube.com/watch?v=uTjCTrT5SCY>

March 28, 2022

Mackey, T. K. Interview and Research Coverage in Silive.com

Grunlund, M. *Drug emoji decoded: Inside the secret language used by drug dealers on the internet and dark web.*

Available at: <https://www.silive.com/crime-safety/2022/03/drug-emoji-decoded-inside-the-secret-language-used-by-drug-dealers-on-the-internet-and-dark-web.html>

April 6, 2022

Mackey, T. K. Interview in Inside Sources

Mallon, E. *Fake Pharma Websites Bring Fentanyl Right to Your Laptop.*

Available at: https://insidesources.com/fake-pharma-websites-bring-fentanyl-right-to-your-laptop/?utm_source=rss&utm_medium=rss&utm_campaign=fake-pharma-websites-bring-fentanyl-right-to-your-laptop

April 7, 2022

Mackey, T. K. Interview and Research Coverage in People

Fleming, A. R. *Counterfeit Meds Sold on Social Media Are Killing Kids: 'My Son Took One Pill and Died,' Says Mom.*

Available at: <https://people.com/health/counterfeit-meds-sold-on-social-media-are-killing-kids-my-son-took-one-pill-and-died-says-mom/>

April 7, 2022

Mackey, T. K. Interview and Research Coverage in the Independent

Hurley, B. *Mother of 13-year-old boy who died of fentanyl overdose raises alarm about fake pills sold on social media.*

Available at: <https://www.independent.co.uk/news/world/americas/teen-son-fentanyl-overdose-counterfeit-pills-b2053337.html>

April 12, 2022

Mackey, T. K. Interview in the Boston Herald

Mallon, E. *Fake Pharma Websites Bring Fentanyl Right to Your Laptop.*

Available at: <https://www.bostonherald.com/2022/04/12/opinion-fake-pharma-websites-bring-fentanyl-right-to-your-laptop/>

April 26, 2022

Mackey, T. K. Interview in the Chemistry World

Albert, H. *Edible, fluorescent silk tags could help stem tide of counterfeit medicines.*

Available at: <https://www.chemistryworld.com/news/edible-fluorescent-silk-tags-could-help-stem-tide-of-counterfeit-medicines/4015578.article>

May 3, 2022

Mackey, T. K. Interview and Research Coverage in Business Insider

Bradbury, R. *TikTok drug sellers are using nose and snowflake emoji and slang to get around search blocks and peddle cocaine and mushrooms.*

Available at: <https://www.businessinsider.com/tiktok-accounts-use-nose-snowflake-emoji-to-advertise-cocaine-shrooms-2022-4>

June 3, 2022

Mackey, T. K. French Public Radio Interview and Research Coverage in Franceinfo

Paour, S. *Aux États-Unis, les opioïdes engendrent toujours plus d'overdoses chez les jeunes : "Ils meurent parce qu'ils ne savent pas ce qu'ils prennent"*.

Available at: https://www.francetvinfo.fr/replay-radio/le-choix-franceinfo/aux-etats-unis-les-opioides-engendrent-toujours-plus-d-overdoses-chez-les-jeunes-ils-meurent-parce-qu-ils-ne-savent-pas-ce-qu-ils-prennent_5148319.html

June 6, 2022

Mackey, T. K. TV Appearance and Interview in Spectrum News 1

City News Service. *Health officials: Tainted drugs contributing to overdose deaths.*

Available at: <https://spectrumnews1.com/ca/la-west/health/2022/05/31/tainted-drugs-contributed-to-3-teen-overdose-deaths>

June 8, 2022

Mackey, T. K. Online Program Video Interview in Newsy

Adkisson, T. *Drug Sales Through Social Media Are Increasing.*

Available at: <https://www.newsny.com/stories/drug-sales-through-social-media-are-increasing/>

July 19, 2022

Mackey, T. K. Interview and Research Coverage in npr.org

Brumfiel, G. *Doubting mainstream medicine, COVID patients find dangerous advice and pills online.*

Available at: <https://www.npr.org/sections/health-shots/2022/07/19/1111794832/doubting-mainstream-medicine-covid-patients-find-dangerous-advice-and-pills-onli>

September 14, 2022

Mackey, T. K. Interview in STAT News

Palmer, K. *'This is pharma's dream': How drugmakers are turning telehealth into a marketing gold mine.*

Available at: <https://www.statnews.com/2022/09/14/pharma-marketing-prescriptions-telehealth-virtual/>